Fintel reports that on January 22, 2025, RBC Capital downgraded their outlook for Intra-Cellular Therapies (NasdaqGS:ITCI) ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) on January 21 and set a price target ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...

However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

We recently compiled a list of the 13 AI News and Ratings on Wall Street’s Radar. In this article, we are going to take a ...

The state of Colorado is moving forward with its plans to purchase Estes Park landmark The Stanley Hotel and fund a ...

Fintel reports that on January 7, 2025, RBC Capital upgraded their outlook for Carvana (NYSE:CVNA) from Sector Perform to Outperform. Analyst Price Forecast Suggests 30.86% Upside As of December ...

Fintel reports that on January 7, 2025, RBC Capital upgraded their outlook for Carvana (LSE:0A79) from Sector Perform to Outperform. There are 997 funds or institutions reporting positions in Carvana.

Acknowledging that there is skepticism surrounding its business model and ability to sustain profitability targets, RBC Capital joins the growing list of bulls in support of Carvana, raising its ...

Fintel reports that on January 6, 2025, RBC Capital downgraded their outlook for T-Mobile US (BRSE:TMUS) from Outperform to Sector Perform. There are 2,603 funds or institutions reporting ...